Dihydropyridine Scaffold Yields New Caspase-1 Blockers
- Reports a new series of caspase-1-targeting small molecules built on a dihydropyridine scaffold, a heterocyclic chemotype more commonly associated with calcium-channel drugs.
- Characterizes inhibitory activity with in vitro fluorescence-based enzymatic assays and extends the work into cell-imaging studies of caspase-1 activity.
- Positions the compounds as early leads given caspase-1's central role in inflammasome-driven inflammatory signaling.
💡 Points
Dihydropyridines have spent decades gating L-type calcium channels, so watching the core get repointed at caspase-1 is a nice reminder that a synthetically tractable, well-behaved scaffold doesn't have to stay in its original target class. The summary is thin on potency and selectivity numbers, though — as written, this reads as chemotype diversification for an inflammasome target, not yet a validated lead.